Canaccord raised the firm’s price target on Exact Sciences (EXAS) to $95 from $75 and keeps a Buy rating on the shares. The firm said they are bullish heading into earnings and 2025 as recent weakness has provided an opportunity to accumulate shares ahead of upcoming catalysts or underappreciated positve factors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences announces FDA approval of Cologuard Plus test
- Exact Sciences price target raised to $80 from $72 at Evercore ISI
- Exact didn’t get Cologuard Plus price hike in preliminary CLFS, says Wolfe
- Exact Sciences price target raised to $82 from $70 at BTIG
- Canaccord sees colon blood test as attractive revenue stream for Exact
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
